Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...
It’s a pill, not an injection, which will likely make it more attractive. Novo Nordisk itself has a new and improved drug under development. Amycretin saw some participants lose 22% of their ...
Stockhead on MSN4d
Ozempic’s PBS push could shake up ASX food stocks, and here’s howBig pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
GlobalData on MSN4d
Super Bowl ad for copycat weight loss drugs stokes pharma power debateControversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback